Q Therapeutics' ALS candidate gets orphan status from FDA

11/19/2013 | Salt Lake Tribune (Utah), The

The FDA granted orphan-drug status to Q Therapeutics' experimental drug Q-Cells as a treatment for amyotrophic lateral sclerosis, or Lou Gehrig's disease. The designation will give the stem cell drug developer several incentives such as tax credits and seven years of market exclusivity.

View Full Article in:

Salt Lake Tribune (Utah), The

Published in Briefs:

SmartBrief Job Listings for Health Care